CN113135996A - 一种双特异抗体及其应用 - Google Patents

一种双特异抗体及其应用 Download PDF

Info

Publication number
CN113135996A
CN113135996A CN202011427863.9A CN202011427863A CN113135996A CN 113135996 A CN113135996 A CN 113135996A CN 202011427863 A CN202011427863 A CN 202011427863A CN 113135996 A CN113135996 A CN 113135996A
Authority
CN
China
Prior art keywords
ser
seq
gly
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011427863.9A
Other languages
English (en)
Chinese (zh)
Inventor
屈向东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qure Biotechnology (Shanghai) Co Ltd
Original Assignee
Qure Biotechnology (Shanghai) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qure Biotechnology (Shanghai) Co Ltd filed Critical Qure Biotechnology (Shanghai) Co Ltd
Priority to EP21901953.6A priority Critical patent/EP4261231A4/en
Priority to PCT/CN2021/094672 priority patent/WO2022121239A1/zh
Priority to US18/256,679 priority patent/US20240043567A1/en
Priority to JP2023535529A priority patent/JP7818838B2/ja
Publication of CN113135996A publication Critical patent/CN113135996A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202011427863.9A 2019-12-09 2020-12-09 一种双特异抗体及其应用 Pending CN113135996A (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP21901953.6A EP4261231A4 (en) 2019-12-09 2021-05-19 Bispecific antibody and application thereof
PCT/CN2021/094672 WO2022121239A1 (zh) 2019-12-09 2021-05-19 一种双特异性抗体及其应用
US18/256,679 US20240043567A1 (en) 2019-12-09 2021-05-19 Bispecific antibody and application thereof
JP2023535529A JP7818838B2 (ja) 2019-12-09 2021-05-19 二重特異性抗体およびその適用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911253241 2019-12-09
CN2019112532416 2019-12-09

Publications (1)

Publication Number Publication Date
CN113135996A true CN113135996A (zh) 2021-07-20

Family

ID=76809347

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011427863.9A Pending CN113135996A (zh) 2019-12-09 2020-12-09 一种双特异抗体及其应用

Country Status (5)

Country Link
US (1) US20240043567A1 (cg-RX-API-DMAC7.html)
EP (1) EP4261231A4 (cg-RX-API-DMAC7.html)
JP (1) JP7818838B2 (cg-RX-API-DMAC7.html)
CN (1) CN113135996A (cg-RX-API-DMAC7.html)
WO (1) WO2022121239A1 (cg-RX-API-DMAC7.html)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110054701A (zh) * 2019-04-17 2019-07-26 中国医学科学院血液病医院(血液学研究所) 一种基于间充质干细胞的抗肿瘤靶向给药系统及其应用
CN113817065A (zh) * 2021-09-06 2021-12-21 深圳市乐土生物医药有限公司 一种抗her2的多肽及其用途
WO2022121239A1 (zh) * 2019-12-09 2022-06-16 启愈生物技术(上海)有限公司 一种双特异性抗体及其应用
CN115246885A (zh) * 2022-06-30 2022-10-28 盛禾(中国)生物制药有限公司 一种双特异性抗体及其应用
WO2022253248A1 (zh) * 2021-06-02 2022-12-08 启愈生物技术(上海)有限公司 抗cd3抗体变异体、融合蛋白及应用
WO2023006082A1 (zh) * 2021-07-30 2023-02-02 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
WO2023020315A1 (zh) * 2021-08-19 2023-02-23 南京吉盛澳玛生物医药有限公司 靶向pd-l1/pd-1的抗体及其应用
WO2023036270A1 (zh) * 2021-09-09 2023-03-16 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
WO2023046116A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种白介素15及其受体的多肽复合物
CN115925967A (zh) * 2021-04-22 2023-04-07 广东菲鹏制药股份有限公司 双特异性多功能融合多肽
CN116178546A (zh) * 2022-10-13 2023-05-30 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
CN116178565A (zh) * 2021-09-24 2023-05-30 广东菲鹏制药股份有限公司 一种双特异性多肽复合物
CN116262786A (zh) * 2021-12-13 2023-06-16 南京融捷康生物科技有限公司 针对folr1的单域抗体及其衍生蛋白和应用
CN116284430A (zh) * 2021-07-30 2023-06-23 广东菲鹏制药股份有限公司 靶向肿瘤的il15融合蛋白及其应用
WO2023138573A1 (zh) * 2022-01-21 2023-07-27 广东菲鹏制药股份有限公司 白细胞介素21及其受体复合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026114362A1 (zh) * 2024-11-29 2026-06-04 正大天晴药业集团股份有限公司 抗体-偶联物、其制备方法及应用
CN119775429B (zh) * 2024-12-26 2026-08-07 南开大学 一种抗人her2/ccr4的双特异性抗体及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US20070160578A1 (en) * 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP6251570B2 (ja) 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体il−15可溶性融合分子並びにその製造及び使用方法
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US20150183877A1 (en) * 2012-07-18 2015-07-02 Eli Lilly And Company Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
JP6510532B2 (ja) * 2013-12-20 2019-05-08 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性her2抗体及び使用方法
EP3093295B1 (en) * 2014-01-08 2020-05-27 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-15 heterogeneous dimer protein and uses thereof
US10905743B2 (en) * 2014-12-19 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex
EP3464352B1 (en) * 2016-05-27 2021-03-24 Altor BioScience Corporation Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
AU2018291497A1 (en) * 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
CN117843810A (zh) * 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
US11168138B2 (en) * 2018-03-26 2021-11-09 Altor Bioscience, Llc Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
KR20210003814A (ko) * 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
CA3097593A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
WO2019204646A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
CN110437339B (zh) * 2018-05-04 2021-08-13 免疫靶向有限公司 一种以白介素15为活性成分的融合蛋白型药物前体
US20220143178A1 (en) * 2019-02-03 2022-05-12 Shanghai Bao Pharmaceuticals Co., Ltd. Anti-her2 bispecific antibody and application thereof
JP7621263B2 (ja) * 2019-02-22 2025-01-24 武▲漢▼友芝友生物制▲薬▼股▲ふん▼有限公司 改変されたFc断片、それを含む抗体、及びそれらの使用
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110054701B (zh) * 2019-04-17 2022-12-27 中国医学科学院血液病医院(血液学研究所) 一种基于间充质干细胞的抗肿瘤靶向给药系统及其应用
CN110054701A (zh) * 2019-04-17 2019-07-26 中国医学科学院血液病医院(血液学研究所) 一种基于间充质干细胞的抗肿瘤靶向给药系统及其应用
WO2022121239A1 (zh) * 2019-12-09 2022-06-16 启愈生物技术(上海)有限公司 一种双特异性抗体及其应用
CN115925967A (zh) * 2021-04-22 2023-04-07 广东菲鹏制药股份有限公司 双特异性多功能融合多肽
WO2022253248A1 (zh) * 2021-06-02 2022-12-08 启愈生物技术(上海)有限公司 抗cd3抗体变异体、融合蛋白及应用
CN116284430A (zh) * 2021-07-30 2023-06-23 广东菲鹏制药股份有限公司 靶向肿瘤的il15融合蛋白及其应用
JP7880160B2 (ja) 2021-07-30 2026-06-25 クレ バイオテクノロジ (シャンハイ) カンパニー リミテッド 抗原ターゲティング、抗cd16aおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用
WO2023006082A1 (zh) * 2021-07-30 2023-02-02 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
JP2024529494A (ja) * 2021-07-30 2024-08-06 クレ バイオテクノロジ (シャンハイ) カンパニー リミテッド 抗原ターゲティング、抗cd16aおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用
WO2023020315A1 (zh) * 2021-08-19 2023-02-23 南京吉盛澳玛生物医药有限公司 靶向pd-l1/pd-1的抗体及其应用
CN113817065A (zh) * 2021-09-06 2021-12-21 深圳市乐土生物医药有限公司 一种抗her2的多肽及其用途
WO2023036270A1 (zh) * 2021-09-09 2023-03-16 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
JP2024534982A (ja) * 2021-09-09 2024-09-26 クレ バイオテクノロジ (シャンハイ) カンパニー リミテッド 抗原ターゲティング、抗cd16aおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用
CN116178565A (zh) * 2021-09-24 2023-05-30 广东菲鹏制药股份有限公司 一种双特异性多肽复合物
WO2023046116A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种白介素15及其受体的多肽复合物
CN116262786A (zh) * 2021-12-13 2023-06-16 南京融捷康生物科技有限公司 针对folr1的单域抗体及其衍生蛋白和应用
WO2023138573A1 (zh) * 2022-01-21 2023-07-27 广东菲鹏制药股份有限公司 白细胞介素21及其受体复合物
CN115246885B (zh) * 2022-06-30 2023-10-24 盛禾(中国)生物制药有限公司 一种双特异性抗体及其应用
CN115246885A (zh) * 2022-06-30 2022-10-28 盛禾(中国)生物制药有限公司 一种双特异性抗体及其应用
WO2024077774A1 (zh) * 2022-10-13 2024-04-18 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用
CN116178546A (zh) * 2022-10-13 2023-05-30 深圳市百士通科技开发有限公司 一种多功能重组抗体及其制备方法和应用

Also Published As

Publication number Publication date
JP7818838B2 (ja) 2026-02-24
WO2022121239A1 (zh) 2022-06-16
JP2023552851A (ja) 2023-12-19
EP4261231A1 (en) 2023-10-18
EP4261231A4 (en) 2024-11-13
US20240043567A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
US20240043567A1 (en) Bispecific antibody and application thereof
JP2023552851A5 (cg-RX-API-DMAC7.html)
JP7681073B2 (ja) 新規インターロイキン2およびその使用
JP7512210B2 (ja) 新規インターロイキン2およびその使用
US10118964B2 (en) Construction and application of bispecific antibody HER2xCD3
CN111518213B (zh) 抗her2的双特异性抗体及其应用
CN113321738A (zh) 肿瘤靶向、抗cd3和t细胞激活三功能融合蛋白及其应用
KR20190052677A (ko) 항-ctla4 및 항-pd-1 이작용성 항체, 이의 약제학적 조성물 및 이의 용도
CN112601546B (zh) Plap-car-效应细胞
CN109415409A (zh) Flag标记的cd19-car-t细胞
WO2023046156A1 (en) Il-2 variants and fusion proteins thereof
JP2021533761A (ja) Ox40結合性ポリペプチド及びその使用
CN104829728A (zh) 一种双特异性抗体her2xcd3的构建及应用
WO2021219127A1 (zh) 一种靶向her2和pd-1的双特异性抗体及其应用
CN113307879A (zh) 一种taa/ctla-4/il15三功能融合蛋白及其应用
CN109666074A (zh) 一种趋化因子受体cxcr5的用途
Richter et al. Receptor-targeted cancer therapy
CN110437340A (zh) 双靶点识别可调控工程化免疫细胞的制备方法
WO2018121679A1 (zh) 表达cxcr4的嵌合抗原受体修饰的淋巴细胞及制备方法和用途
Hu et al. Epitope mapping and structural analysis of an anti‐ErbB2 antibody A21: molecular basis for tumor inhibitory mechanism
CN102492039A (zh) 全人源抗人her2单抗
CN118159568A (zh) 一种融合多肽及其用途
CN101948540B (zh) 抗egfr人源抗体mil27的设计及其应用
Hosseini-Ghatar et al. Epitope mapping of human HER2 specific mouse monoclonal antibodies using recombinant extracellular subdomains of HER2
Ghatar et al. Epitope mapping of human HER2 specific mouse monoclonal antibodies using recombinant extracellular subdomains

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination